Skip to search formSkip to main contentSkip to account menu

bectumomab

Known as: IMMU-LL2-Fab, MAb LL2 (EPB2), monoclonal antibody IMMU-LL2-Fab 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
Diffuse Large B-Cell Lymphomas (DLBCLs) are the most common histologic subtype within non-Hodgkin’s lymphomas (NHLs), accounting… 
Review
2009
Review
2009
Received 2 March 2009; accepted 3 March 2009; electronically published 15 May 2009. Reprints or correspondence: Dr. Atul Humar… 
2008
2008
On January 1, 2000, Medicare extended the coverage of immunosuppression medications from 3 years to life for elderly and disabled… 
2004
2004
Mangeat B, Turelli P, Caron G, et al. Nature. 2003;424:99–102 Innate intracellular antiretroviral defense mechanisms have been… 
2002
2002
UNLABELLED The efficacy of a Tc99m-labeled anti-lymphoma antibody fragment, bectumomab [LymphoScan], was retrospectively examined… 
1996
1996
Dr. Hatem Mansy, Senior Consultant Nephrologist, North West Armed Forces, Hospitals Program, Tabuk (Saudi Arabia) Dear Sir… 
1993
1993
In the last 20 years an unusually high incidence of acute promy-elocytic leukemia (APL) has been observed at the Monza pediatric… 
Highly Cited
1988
Highly Cited
1988
We have demonstrated that one Fc receptor for IgG (FcR) (CD16) on cultured human monocytes appears to be a developmentally… 
Highly Cited
1975
Highly Cited
1975